2. Signaling Pathways
  3. Immunology/Inflammation
  4. TROP2
  5. TROP2 Inhibitor

TROP2 Inhibitor

TROP2 Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-132254
    Sacituzumab govitecan
    		Inhibitor 98.00%
    Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.
  • HY-P99045
    Sacituzumab
    		Inhibitor 99.77%
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer.
  • HY-141598
    Datopotamab deruxtecan
    		Inhibitor
    Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.
  • HY-P99843
    Datopotamab
    		Inhibitor 98.62%
    Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.
  • HY-132254A
    Sacituzumab govitecan (solution)
    		Inhibitor
    Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.
  • HY-164789
    Sacituzumab tirumotecan
    		Inhibitor
    Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC).